Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosageChun‐Jen Liu, Pei‐Jer Chen, Stanley Shi-Chung Chang et al.|Journal of Hepatology|2009Cited by 157
Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinomaRey‐Heng Hu, Po‐Huang Lee, Ming‐Chih Ho et al.|Clinical Transplantation|2005Cited by 52
1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant RecipientsHsin‐Yun Sun, Shan‐Chwen Chang, Cheng‐Maw Ho et al.|Open Forum Infectious Diseases|2019Cited by 1